Relacorilant PDUFA Date (Corcept Therapeutics)
FDA PDUFA decision date for Relacorilant is July 11, 2026. Developed by Corcept Therapeutics. Indication: Platinum-resistant ovarian cancer. Current status: Verifying.
Indication
Platinum-resistant ovarian cancer
Notes
Cortisol modulator + nab-paclitaxel combo. New mechanism.
Regulatory details
- Company: Corcept Therapeutics
- Therapeutic area: Oncology
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-07-11
- Outcome: Pending